NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD
Taking everything into account, CUE scores 3 out of 10 in our fundamental rating. CUE was compared to 551 industry peers in the Biotechnology industry. The financial health of CUE is average, but there are quite some concerns on its profitability. CUE is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -182.37% | ||
ROE | -616.78% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -25.59 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.03 | ||
Quick Ratio | 1.03 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:CUE (8/5/2025, 8:07:05 PM)
0.8381
+0.08 (+9.99%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 7.9 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 9.6 | ||
P/tB | 9.6 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -182.37% | ||
ROE | -616.78% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 40.35% | ||
Cap/Sales | 2.01% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.03 | ||
Quick Ratio | 1.03 | ||
Altman-Z | -25.59 |